FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington	D.C. 20549	

n D C 20E40	
n, D.C. 20549	
	│ OMB APPROVAL

- 1		
	OMB Number:	3235-0287
	Estimated average burden	
	hours per response:	0.5

	Check this box if no longer subject to
ì	Section 16. Form 4 or Form 5
J	obligations may continue. See
	Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MACKAY MARTIN			2. Issuer Name and Ticker or Trading Symbol Rallybio Corp [RLYB]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
MACKAY M	AKIIN		*****	<u>, 210 COIP</u> [N					X	Director	10%	Owner		
(Last)	(First)							X	Officer (give title below)	Othe below	r (specify v)			
(Last) (First) (Middle) C/O RALLYBIO CORPORATION				3. Date of Earliest Transaction (Month/Day/Year) 07/28/2021						Chief Executive Officer				
234 CHURCH S	FREET, SUITE 10)20												
(Street) NEW HAVEN (City)	CT (State)	06510	4. If Ar	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Indiv	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)												
		Table I - Noi	n-Derivative	Securities Ac	quired	l, Dis	sposed of,	or Ben	eficially C	wned				
Date			2. Transaction Date (Month/Day/Year)	Execution Date,		ction Instr.	4. Securities A Disposed Of (I	cquired (A D) (Instr. 3	A) or , 4 and 5)	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership		
		`		(Month/Day/Year)	8)						(I) (Instr. 4)			
				(Month/Day/Year)	8) Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(I) (Instr. 4)	(Instr. 4)		
Common Stock			07/28/2021	(Month/Day/Year)	Ė	v	Amount 272,609	(A) or (D)	Price (1)	Reported Transaction(s)	(i) (Instr. 4)			
Common Stock Common Stock			07/28/2021 07/28/2021	(Month/Day/Year)	Code	v				Reported Transaction(s) (Instr. 3 and 4)				
				(Montn/Day/Year)	Code J ⁽¹⁾	v	272,609	A	(1)	Reported Transaction(s) (Instr. 3 and 4) 272,609		See		
Common Stock			07/28/2021	(MONTH/Day/Year)	Code J ⁽¹⁾ J ⁽¹⁾	v	272,609 436,517	A A	(1)	Reported Transaction(s) (Instr. 3 and 4) 272,609 436,517	D I	See		

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Common Units	(1)	07/28/2021		J ⁽¹⁾			2,255,001	(1)	(1)	Common Stock	272,609	(1)	0	D	
Common Units	(1)	07/28/2021		J ⁽¹⁾			2,564,999	(1)	(1)	Common Stock	380,312	(1)	0	I	See Footnote ⁽²⁾
Series A-1 Preferred Units	(1)	07/28/2021		J ⁽¹⁾			150,000	(1)	(1)	Common Stock	23,557	(1)	0	I	See Footnote ⁽²⁾
Series A-2 Preferred Units	(1)	07/28/2021		J ⁽¹⁾			100,000	(1)	(1)	Common Stock	15,704	(1)	0	I	See Footnote ⁽²⁾
Series B Preferred Units	(1)	07/28/2021		J ⁽¹⁾			107,891	(1)	(1)	Common Stock	16,944	(1)	0	I	See Footnote ⁽²⁾
Option (Right to Buy)	\$13	07/28/2021		A		160,000		(5)	07/28/2031	Common Stock	160,000	\$0.00	160,000	D	

Explanation of Responses:

- 1. The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units, the "Preferred Units") reported Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported Units (collectively with the Series A-1 Preferred Units, the "Preferred Units") reported Units (collectively with the Series A-1 Preferred Units, the "Preferred Units") reported Units (collectively with the Series A-1 Preferred Units, the "Preferred Units") reported Units (collectively with the Series A-1 Preferred Units, the "Preferred Units") reported Units (collectively with the Series A-1 Preferred Units, the "Preferred Units") reported Units (collectively with the Series A-1 Preferred Units) reported Units (collectively with the Series A-2 Preferred Units) reported Units (collectively with the Series A-2 Preferred Units) reported Units (collectively with the Series A-2 Preferred Units) reported Units (collectively with the Series A-2 Preferred Units) reported Units (collectively with the Series A-2 Preferred Units) reported Units (collectively with the Series A-2 Preferred Units) reported Units (collectively with the Series A-2 Preferred Units) reported Units (collectively with the Series A-2 Preferred Units) reported Units (collectively with the Series A-2 Preferred Units) reported Units (collectively with the Series A-2 Preferred Units) reported Units (collectively with the Series A-2 Preferred Units) reported Units (collectively with the Series A-2 Preferred Units) reported Units (collectively with the Series A-2 Preferred Units) reported Units (collectively with the Series A-2 Preferred Units) reported Units (collectively with the Series A-2 Preferred Units) reported Units (collectively with the Series A-2 Preferred Units) reported Units (collectively with the Series A-2 Preferred Units) reported Units (collectively with the Series A-2 Preferred Units) reported Units (collectively with the Series A-2 Preferred Units) reported Units (collectively with the Series A-2 Preferred Un herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Units had no expiration date prior to the liquidation
- 2. Shares of common stock are held directly by a limited liability company, of which Martin Mackay is the managing member. As a result, Dr. Mackay may be deemed to share beneficial ownership of the shares held by the limited liability company.
- 3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$9.66 to \$10.65, inclusive. The reporting person undertakes to provide to Rallybio Corporation, any security holder of Rallybio Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.
- 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$10.01 to \$11.00, inclusive.
- 5. The option vests as to 25% of the underlying shares of Common Stock on July 28, 2022 and as to the remaining 75% of the underlying shares of Common Stock in 36 equal monthly installments thereafter.

Remarks:

/s/ Michael Greco, Attorney-in-

01/12/2022

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.